Ceryvyn Therapeutics (ASX:CYV) Total Payout Ratio: 0.22 (As of Jul. 11, 2026)


What is Ceryvyn Therapeutics Total Payout Ratio?

Ceryvyn Therapeutics ASX:CYV -7.69% Total Payout Ratio is 0.22 as of Jul. 11, 2026. The stock has 3 warning signs investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Ceryvyn Therapeutics's current Total Payout Ratio is 0.22.

Ceryvyn Therapeutics Total Payout Ratio Related Terms

Ceryvyn Therapeutics Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Total Payout Ratio Chart

Ceryvyn Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.33 0.00 0.57 0.72 0.21

Ceryvyn Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.53 0.89 0.26 0.00

ASX:CYV vs VRTX, REGN, ALNY: Total Payout Ratio Comparison

For the Biotechnology subindustry, Ceryvyn Therapeutics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ceryvyn Therapeutics Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Ceryvyn Therapeutics's Total Payout Ratio falls into.


Ceryvyn Therapeutics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Ceryvyn Therapeutics's Total Payout Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 53.467 + 0) / -250.047
=0.21

Ceryvyn Therapeutics's Total Payout Ratio for the quarter that ended in Jun. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0.02 + 0) / -47.422
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 0.22 mean?
Ceryvyn Therapeutics (ASX:CYV) has a Total Payout Ratio of 0.22 as of Jul. 11, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Ceryvyn Therapeutics and its competitors.
Is Ceryvyn Therapeutics' Total Payout Ratio too high?
Ceryvyn Therapeutics' current Total Payout Ratio is 0.22.
How does Ceryvyn Therapeutics' Total Payout Ratio compare to VRTX and REGN?
Ceryvyn Therapeutics' Total Payout Ratio of 0.22 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Ceryvyn Therapeutics and its competitors. Ceryvyn Therapeutics's current Total Payout Ratio is 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current Total Payout Ratio of 0.22. The current Total Payout Ratio is 0.22. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current Total Payout Ratio is 0.22 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.